Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XOMA 213 for postpartum suppression of lactation
2015-005751-27Phase 2Completed
- Sponsor
- XOMA
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LFA102 (2 arms), sponsored by XOMA. Primary endpoints: Safety and tolerability of XOMA 213 and Pharmacokinetics of XOMA 213. Started Mar 2016; status: completed.
02
Drugs
LFA102
Beyond the preview
Go deeper on 2015-005751-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005751-27.